Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- Ovarian Cancer
- Registration Number
- NCT00179712
- Lead Sponsor
- Celgene Corporation
- Brief Summary
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-14 when given with topotecan on days 1-5 of every 21 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-14 with topotecan on days 1-5 in 21 day cycles until disease progression is documented.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
- Subjects must understand and voluntarily sign an informed consent document.
- Age >or = to 18 years at the time of signing informed consent form.
- Subjects must be able to adhere to the study visit schedule and other protocol requirements.
- Histological or cytological documentation of advanced ovarian or primary peritoneal carcinoma.
- Radiographic or clinical evidence of measurable metastatic advanced ovarian or primary peritoneal carcinoma. Subjects must have measurable disease at least 2 cm in diameter.
- Subjects must have been treated and progressed following chemotherapy which includes platinum and paclitaxel.
- ECOG performance status of 0 or 1 (Appendix I: ECOG Performance Status Scale).
-
Any of the following laboratory abnormalities:
- Absolute neutrophil count (ANC) <1,500 cells/mm3 (1.5 x 109/L)
- Platelet count <100,000 cells/mm3 (100 x 109/L)
- Serum creatinine >1.5 mg/dL (133 mmol/L)
- Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
- Serum total bilirubin >2.0 mg/dL (34 mmol/L)
-
Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent.
-
Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the breast) unless the subject has been free of disease for > 1 year.
-
Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in case of clinical suspicion of central nervous system involvement).
-
More than 1 prior chemotherapy regimen. However, subjects with platinum sensitive disease (i.e., subjects who fail a platinum containing regimen at least six months after completing the regimen) who are retreated with a platinum containing regimen are eligible.
-
Concurrent use of any other anti-cancer agents.
-
Any prior use of lenalidomide.
-
Prior > or = to grade 3 (see Appendix III) rash or any desquamating (blistering) rash while taking thalidomide.
-
Prior . Or = to grade 3 (see Appendix III) allergic reaction/hypersensitivity to thalidomide.
-
Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.
-
Known active Hepatitis C.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Primary Outcome Measures
Name Time Method Phase II-To explore the anti-tumor activity based on objective response rate (CR + PR) of the combination of oral lenalidomide and topotecan Phase I-To determine the MTD and evaluate the safety profile of oral lenalidomide and topotecan
- Secondary Outcome Measures
Name Time Method Phase I-To explore the anti-tumor activity based on response of the combination of lenalidomide and topotecan. Phase II-To explore the safety profile of the combination of lenalidomide and topotecan
Trial Locations
- Locations (3)
Medical College of GeorgiaDept of OBGYN
🇺🇸Augusta, Georgia, United States
University of MinnesotaObstetrics & Gynecology, MMC
🇺🇸Minneapolis, Minnesota, United States
Ohio State University
🇺🇸Columbus, Ohio, United States